Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) was downgraded by analysts at Leerink Partners from an “outperform” rating to a “market perform” rating in a research note issued on Tuesday, Marketbeat Ratings reports. They currently have a $4.00 target price on the stock. Leerink Partners’ price objective would suggest a potential downside of 37.69% from the stock’s previous close.
A number of other brokerages also recently weighed in on FULC. HC Wainwright downgraded Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and set a $3.00 price objective on the stock. in a research report on Tuesday. Piper Sandler downgraded Fulcrum Therapeutics from an “overweight” rating to an “underweight” rating and set a $3.00 price objective on the stock. in a research report on Tuesday. Wall Street Zen raised Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Tuesday, April 21st. Finally, Stifel Nicolaus downgraded Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $3.00 price objective on the stock. in a research report on Tuesday. Three equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $8.20.
Get Our Latest Stock Report on Fulcrum Therapeutics
Fulcrum Therapeutics Trading Down 7.2%
Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) last announced its quarterly earnings results on Monday, April 27th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.06. Analysts forecast that Fulcrum Therapeutics will post -1.16 earnings per share for the current year.
Institutional Trading of Fulcrum Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in FULC. Braidwell LP increased its position in shares of Fulcrum Therapeutics by 1,294.7% in the fourth quarter. Braidwell LP now owns 3,061,222 shares of the company’s stock valued at $34,622,000 after buying an additional 2,841,734 shares in the last quarter. Siren L.L.C. purchased a new stake in shares of Fulcrum Therapeutics in the fourth quarter valued at approximately $22,054,000. First Turn Management LLC purchased a new stake in shares of Fulcrum Therapeutics in the fourth quarter valued at approximately $21,406,000. GSK plc purchased a new stake in shares of Fulcrum Therapeutics during the fourth quarter worth approximately $20,196,000. Finally, Adage Capital Partners GP L.L.C. increased its position in shares of Fulcrum Therapeutics by 53.0% during the second quarter. Adage Capital Partners GP L.L.C. now owns 4,589,000 shares of the company’s stock worth $31,572,000 after purchasing an additional 1,589,000 shares in the last quarter. 89.83% of the stock is currently owned by hedge funds and other institutional investors.
About Fulcrum Therapeutics
Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.
Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.
Read More
- Five stocks we like better than Fulcrum Therapeutics
- 5 Reasons to Pony Up for Pony AI Stock—and 1 Reason to Wait
- Will the SpaceX IPO Put These 5 Public Space Stocks Into a Higher Orbit?
- Palantir’s Drone Tailwind Puts Its Defense AI Story Back in Focus for Investors
- Why 1 Little-Known ETF Is Riding the AI Chip Shortage
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
